Broad Institute

Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.

The centers will generate genomic data from biosamples contributed by participants in the program and analyze data that will be returned to them.

Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.

Researchers used fine mapping and other approaches to prioritize proposed coding and non-coding causal variants at rheumatoid arthritis- and type 1 diabetes-linked loci.

The researchers analyzed whole-exome sequencing data from 249 tumors and matched normal tissue from patients with known outcomes to immunotherapy.